Lu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lu Wang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Cong Li
Department of Urology Harbin Medical University Cancer Hospital Harbin China
3 shared publicationsHuanfeng Liu
Medical Center of Hematology, State Key Laboratory of Trauma, Burn and Combined Injury, Xinqiao Hospital, Army Medical University, Chongqing, China
3 shared publications- Lei Gao
Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China
3 shared publications - Lidan Zhu
Army medical University affiliated Xinqiao Hospital, Chongqing, China
3 shared publications Lingrui Jian
NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy Harbin Medical University Harbin China
3 shared publications- Pei-Yan Kong
Xinqiao Hospital of Army Medical University, Medical Centre of Hematology, Chongqing, China
3 shared publications
Latest Publications
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (36)
SR‐B1‐Targeted Cholesterol Depletion Nanosystem Synergizes Cholesterol Metabolic Reprogramming and Immunotherapy for Clear Cell Renal Cell Carcinoma
Metabolic reprogramming, particularly dysregulated cholesterol homeostasis, represents a critical vulnerability in clear cell renal cell carcinoma (ccRCC). Herein, we identify scavenger receptor class B type 1 (SR‐B1) as a pivotal mediator of exogenous cholesterol uptake in ccRCC, driving intracellular cholesterol overaccumulation that promotes tumor malignancy and immunosuppressive microenvironment formation. We engineered an SR‐B1‐targeted cholesterol depletion nanosystem (CDN), which self‐assembles into supramolecular nanofibers upon ligand binding, thereby disrupting SR‐B1 function and depleting intracellular cholesterol to inhibit malignant progression and reverse immune suppression. Given that metabolic depletion of cholesterol primes the tumor microenvironment for immune activation, we integrated resiquimod (R848), a toll‐like receptor 7/8 agonist, into CDN. This dual strategy synergizes cholesterol metabolic reprogramming with immunotherapy: it starves tumors of critical metabolic substrates (targeting cholesterol intrinsic dependencies) while inducing sustained antitumor immune activation (alleviating extrinsic immunosuppression), culminating in robust antitumor responses superior to monotherapies. Our study establishes SR‐B1 as a therapeutic target linking cholesterol metabolism and immune regulation in ccRCC, demonstrating that receptor‐specific metabolic intervention can synergize with immunotherapy by addressing both tumor intrinsic dependencies and extrinsic immune suppression. This integrated strategy provides a mechanistic framework for developing next‐generation combination therapies in metabolic‐driven cancers.
- 15 February 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (36)
SR‐B1‐Targeted Cholesterol Depletion Nanosystem Synergizes Cholesterol Metabolic Reprogramming and Immunotherapy for Clear Cell Renal Cell Carcinoma
Metabolic reprogramming, particularly dysregulated cholesterol homeostasis, represents a critical vulnerability in clear cell renal cell carcinoma (ccRCC). Herein, we identify scavenger receptor class B type 1 (SR‐B1) as a pivotal mediator of exogenous cholesterol uptake in ccRCC, driving intracellular cholesterol overaccumulation that promotes tumor malignancy and immunosuppressive microenvironment formation. We engineered an SR‐B1‐targeted cholesterol depletion nanosystem (CDN), which self‐assembles into supramolecular nanofibers upon ligand binding, thereby disrupting SR‐B1 function and depleting intracellular cholesterol to inhibit malignant progression and reverse immune suppression. Given that metabolic depletion of cholesterol primes the tumor microenvironment for immune activation, we integrated resiquimod (R848), a toll‐like receptor 7/8 agonist, into CDN. This dual strategy synergizes cholesterol metabolic reprogramming with immunotherapy: it starves tumors of critical metabolic substrates (targeting cholesterol intrinsic dependencies) while inducing sustained antitumor immune activation (alleviating extrinsic immunosuppression), culminating in robust antitumor responses superior to monotherapies. Our study establishes SR‐B1 as a therapeutic target linking cholesterol metabolism and immune regulation in ccRCC, demonstrating that receptor‐specific metabolic intervention can synergize with immunotherapy by addressing both tumor intrinsic dependencies and extrinsic immune suppression. This integrated strategy provides a mechanistic framework for developing next‐generation combination therapies in metabolic‐driven cancers.
- 5 February 2026
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 13 (8) , 4056-4071
Supramolecular net-suppressor drives tumor vascular-immune microenvironment remodeling with spatiotemporal synchronization for renal cancer therapy
Our RING strategy employs a cyclic peptide integrating three modules: (i) dual VEGF/Tie2 targeting for vascular remodeling; (ii) a β-sheet self-assembly motif forming nanofibers; (iii) a D-TIGIT blocking peptide to restore anti-tumor immunity.
- 5 February 2026
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 13 (8) , 4056-4071
Supramolecular net-suppressor drives tumor vascular-immune microenvironment remodeling with spatiotemporal synchronization for renal cancer therapy
Our RING strategy employs a cyclic peptide integrating three modules: (i) dual VEGF/Tie2 targeting for vascular remodeling; (ii) a β-sheet self-assembly motif forming nanofibers; (iii) a D-TIGIT blocking peptide to restore anti-tumor immunity.
- 13 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64232-64243
Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Renal cancer is a highly vascularized tumor, and tumor vasculature accelerates the progression and metastasis of renal cancer. Vascular endothelial growth factor (VEGF) and TIE-2 are the two most essential factors that facilitate tumor angiogenesis; additionally, VEGF has an angiogenesis-independent function in cancer cells that enhances their malignant progression. The long-term inhibition of dual targets, blood vessels and tumor cells, can effectively prevent the progression and metastasis of renal cancer. This study developed a transformable kidney cancer targeting responsive nanopeptide probe (RTP) for the construction of nanofibers in renal cell carcinoma (RCC), which helped to significantly inhibit tumor neovascularization and progression through dual targets. The results showed that RTP reduced angiogenesis to 35.26% ± 4.78% by inhibiting VEGF and TIE-2 and increased tumor cell apoptosis by 6-fold. In vivo validation experiments showed that RTP significantly inhibited tumor angiogenesis and progression. The innovative RTP significantly inhibits renal cancer angiogenesis and may provide a new way to inhibit renal cancer blood vessels and cancer cells.
- 13 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64232-64243
Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Renal cancer is a highly vascularized tumor, and tumor vasculature accelerates the progression and metastasis of renal cancer. Vascular endothelial growth factor (VEGF) and TIE-2 are the two most essential factors that facilitate tumor angiogenesis; additionally, VEGF has an angiogenesis-independent function in cancer cells that enhances their malignant progression. The long-term inhibition of dual targets, blood vessels and tumor cells, can effectively prevent the progression and metastasis of renal cancer. This study developed a transformable kidney cancer targeting responsive nanopeptide probe (RTP) for the construction of nanofibers in renal cell carcinoma (RCC), which helped to significantly inhibit tumor neovascularization and progression through dual targets. The results showed that RTP reduced angiogenesis to 35.26% ± 4.78% by inhibiting VEGF and TIE-2 and increased tumor cell apoptosis by 6-fold. In vivo validation experiments showed that RTP significantly inhibited tumor angiogenesis and progression. The innovative RTP significantly inhibits renal cancer angiogenesis and may provide a new way to inhibit renal cancer blood vessels and cancer cells.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6975
Application Gene Variation Detection before and after Hematopoietic Stem Cell Transplantation to Predict the Relapse of Hematopoietic Neoplasm Patients after Transplantation: Retrospective Data from a Single Center in China
Disclosures. No relevant conflicts of interest to declare.
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6975
Open AccessApplication Gene Variation Detection before and after Hematopoietic Stem Cell Transplantation to Predict the Relapse of Hematopoietic Neoplasm Patients after Transplantation: Retrospective Data from a Single Center in China
Disclosures. No relevant conflicts of interest to declare.
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e83537cc
P1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e83537cc
Open AccessP1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e7027398
PB2433: APPLICATION GENE VARIATION DETECTION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RELAPSE OF PATIENTS AFTER TRANSPLANTATION: RETROSPECTIVE DATA FROM A SINGLE CENTER IN CHINA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e7027398
Open AccessPB2433: APPLICATION GENE VARIATION DETECTION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RELAPSE OF PATIENTS AFTER TRANSPLANTATION: RETROSPECTIVE DATA FROM A SINGLE CENTER IN CHINA
- Open Access
- 2 August 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (9) , e23118
LncRNA PVT1 promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells
Renal cancer stem cells (RCSCs) derived from clear cell renal cell carcinoma (ccRCC) tissues with higher microvessel density (MVD) have strong stemness and endothelial progenitor cells‐like (EPCs‐like) characteristics. A high level of lncRNA PVT1 expression is essential for simultaneously retaining strong RCSC stemness and EPCs‐like characteristics. PVT1 binds with TAZ protein and prevents its phosphorylation, which promotes RCSC stemness. Moreover, RCSCs support endothelial differentiation and angiogenesis, which are mediated via the PVT1/miR‐15b/KDR axis. This report provides insight into the determinants of RCSC impact on stemness and highlights the critical role of RCSC in angiogenesis. The presented findings suggest that targeting RCSC through PVT1 expression may be a new treatment strategy for ccRCC.
- 2 August 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (9) , e23118
Open AccessLncRNA PVT1 promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells
Renal cancer stem cells (RCSCs) derived from clear cell renal cell carcinoma (ccRCC) tissues with higher microvessel density (MVD) have strong stemness and endothelial progenitor cells‐like (EPCs‐like) characteristics. A high level of lncRNA PVT1 expression is essential for simultaneously retaining strong RCSC stemness and EPCs‐like characteristics. PVT1 binds with TAZ protein and prevents its phosphorylation, which promotes RCSC stemness. Moreover, RCSCs support endothelial differentiation and angiogenesis, which are mediated via the PVT1/miR‐15b/KDR axis. This report provides insight into the determinants of RCSC impact on stemness and highlights the critical role of RCSC in angiogenesis. The presented findings suggest that targeting RCSC through PVT1 expression may be a new treatment strategy for ccRCC.
- Open Access
- 9 June 2020
- Published by Wiley in Brain and Behavior
- Vol. 10 (7) , e01643
Left ventricular ejection fraction as an independent predictor of poor outcome in acute intracerebral hemorrhage
Introduction: Few studies of the effect of cardiac abnormalities on acute intracerebral hemorrhage (ICH) outcomes have been published. We sought to determine whether the left ventricular ejection fraction (LVEF) is associated with the functional outcome and mortality of acute ICH patients.Methods: We conducted a retrospective study on 364 acute ICH patients from January to December 2016. The primary outcome was defined by the modified Rankin Scale and mortality at 3 months. The associations between LVEF and outcome were investigated using univariable and multivariable logistic regression models.Results: Depressed LVEF was significantly associated with a poor functional outcome with an odds ratio [OR] of 0.966, 95% confidence interval (CI) 0.942–0.991, p = .008, and high mortality (OR 0.968 [95% CI 0.943–0.994], p = .015) at 3 months for acute ICH patients by univariate analysis. Multivariable logistic regression analysis indicated that LVEF was an independent predictor of a poor functional outcome (OR 0.961 [95% CI 0.935–0.988], p = .005) and mortality (OR 0.949 [95% CI 0.918–0.981], p = .002). The percentage of acute ICH patients with poor functional outcome (p = .005) and mortality (p = .002) was obviously higher in the group of patients with a LVEF of <50%.Conclusions: LVEF is an independent predictor of functional outcome and mortality at 3 months for acute ICH patients. These findings could provide the evidence needed for prognosis prediction in acute ICH patients.
- 9 June 2020
- Published by Wiley in Brain and Behavior
- Vol. 10 (7) , e01643
Open AccessLeft ventricular ejection fraction as an independent predictor of poor outcome in acute intracerebral hemorrhage
Introduction: Few studies of the effect of cardiac abnormalities on acute intracerebral hemorrhage (ICH) outcomes have been published. We sought to determine whether the left ventricular ejection fraction (LVEF) is associated with the functional outcome and mortality of acute ICH patients.Methods: We conducted a retrospective study on 364 acute ICH patients from January to December 2016. The primary outcome was defined by the modified Rankin Scale and mortality at 3 months. The associations between LVEF and outcome were investigated using univariable and multivariable logistic regression models.Results: Depressed LVEF was significantly associated with a poor functional outcome with an odds ratio [OR] of 0.966, 95% confidence interval (CI) 0.942–0.991, p = .008, and high mortality (OR 0.968 [95% CI 0.943–0.994], p = .015) at 3 months for acute ICH patients by univariate analysis. Multivariable logistic regression analysis indicated that LVEF was an independent predictor of a poor functional outcome (OR 0.961 [95% CI 0.935–0.988], p = .005) and mortality (OR 0.949 [95% CI 0.918–0.981], p = .002). The percentage of acute ICH patients with poor functional outcome (p = .005) and mortality (p = .002) was obviously higher in the group of patients with a LVEF of <50%.Conclusions: LVEF is an independent predictor of functional outcome and mortality at 3 months for acute ICH patients. These findings could provide the evidence needed for prognosis prediction in acute ICH patients.